Plasmid Encoded Il-12
Recurrent Anal Canal Carcinoma
M.D. Anderson Cancer CentervaccinePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Recurrent Anal Canal Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin ECOG-ACRIN Cancer Research Group | Phase 2 | B |
FLUOROURACILUM ECOG-ACRIN Cancer Research Group | Phase 2 | B |
CIS-DIAMMINEDICHLOROPLATINUM II M.D. Anderson Cancer Center | Phase 2 | B |
Toripalimab Sun Yat-sen University | Phase 2 | B |
Durvalumab M.D. Anderson Cancer Center | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
Plasmid Encoded Il-12 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →